hydroxymethylglutaryl coa reductase inhibitors

Summary

Summary: Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.

Top Publications

  1. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
  2. ncbi Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
  3. ncbi Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    C Baigent
    Lancet 366:1267-78. 2005
  4. ncbi Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
    Christoph Wanner
    Division of Nephrology, Department of Medicine, University of Wurzburg, Wurzburg, Germany
    N Engl J Med 353:238-48. 2005
  5. pmc Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
    M R Law
    Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London EC1M 6BQ
    BMJ 326:1423. 2003
  6. ncbi HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    Philip Barter
    Heart Research Institute, Sydney, Australia
    N Engl J Med 357:1301-10. 2007
  7. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    Scott M Grundy
    J Am Coll Cardiol 44:720-32. 2004
  8. ncbi Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 359:2195-207. 2008
  9. ncbi Statins for the prevention and treatment of infections: a systematic review and meta-analysis
    Imad M Tleyjeh
    Department of Medicine, King Fahd Medical City, Riyadh, Saudi Arabia
    Arch Intern Med 169:1658-67. 2009
  10. ncbi Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1495-504. 2004

Detail Information

Publications299 found, 100 shown here

  1. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  2. ncbi Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
    ..We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD)...
  3. ncbi Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    C Baigent
    Lancet 366:1267-78. 2005
    ..But each separate trial has limited power to assess particular outcomes or particular categories of participant...
  4. ncbi Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
    Christoph Wanner
    Division of Nephrology, Department of Medicine, University of Wurzburg, Wurzburg, Germany
    N Engl J Med 353:238-48. 2005
    ..However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined...
  5. pmc Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
    M R Law
    Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London EC1M 6BQ
    BMJ 326:1423. 2003
    ..To determine by how much statins reduce serum concentrations of low density lipoprotein (LDL) cholesterol and incidence of ischaemic heart disease (IHD) events and stroke, according to drug, dose, and duration of treatment...
  6. ncbi HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    Philip Barter
    Heart Research Institute, Sydney, Australia
    N Engl J Med 357:1301-10. 2007
    ..High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol...
  7. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    Scott M Grundy
    J Am Coll Cardiol 44:720-32. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  8. ncbi Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 359:2195-207. 2008
    ....
  9. ncbi Statins for the prevention and treatment of infections: a systematic review and meta-analysis
    Imad M Tleyjeh
    Department of Medicine, King Fahd Medical City, Riyadh, Saudi Arabia
    Arch Intern Med 169:1658-67. 2009
    ..Our objective was to examine the association between statin use and the risk of infections and related outcomes...
  10. ncbi Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1495-504. 2004
    ..Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear...
  11. ncbi Current perspectives on statins
    D J Maron
    Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University, School of Medicine, Nashville, TN 37232 6300, USA
    Circulation 101:207-13. 2000
    ..Mechanisms independent of LDL lowering may play an important role in the clinical benefits conferred by these drugs and may ultimately broaden their indication from lipid-lowering to antiatherogenic agents...
  12. ncbi Stimulation of bone formation in vitro and in rodents by statins
    G Mundy
    OsteoScreen, 2040 Babcock Road, San Antonio, TX 78229, USA
    Science 286:1946-9. 1999
    ..Thus, in appropriate doses, statins may have therapeutic applications for the treatment of osteoporosis...
  13. ncbi Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial
    James A de Lemos
    Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas Southwestern Medical Center, Dallas 75390 9047, USA
    JAMA 292:1307-16. 2004
    ..Limited data are available evaluating how the timing and intensity of statin therapy following an acute coronary syndrome (ACS) event affect clinical outcome...
  14. ncbi Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
    Bengt C Fellström
    Department of Medical Science, Renal Unit, University Hospital, SE 751 85, Uppsala, Sweden
    N Engl J Med 360:1395-407. 2009
    ..Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved...
  15. ncbi Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study
    Eric Bruckert
    Department of Endocrinology, Hopital de la Pitie Salpetriere, Assistance Publique Hôpitaux de Paris 83 Bd de L Hôpital, 75 013, Paris, France
    Cardiovasc Drugs Ther 19:403-14. 2005
    ..To characterize the risk factors, rate of occurrence, onset, nature and impact of mild to moderate muscular symptoms with high-dosage HMG-CoA reductase inhibitor (statin) therapy in general practice...
  16. ncbi Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 352:29-38. 2005
    ..Intensive treatment produced greater reductions in both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship between these two biomarkers and disease progression...
  17. ncbi Anti-inflammatory effects of statins: clinical evidence and basic mechanisms
    Mukesh K Jain
    Program in Cardiovascular Transcriptional Biology, Cardiovascular Division, Brigham and Womens Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
    Nat Rev Drug Discov 4:977-87. 2005
    ..Here, we discuss the clinical and experimental evidence underlying the anti-inflammatory effects of these agents...
  18. ncbi Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:438-45. 2006
    ..The purpose of this study was to conduct a meta-analysis that compares the reduction of cardiovascular outcomes with high-dose statin therapy versus standard dosing...
  19. ncbi Long-term follow-up of the West of Scotland Coronary Prevention Study
    Ian Ford
    Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
    N Engl J Med 357:1477-86. 2007
    ..9 to 5.5% (P<0.001) in the treatment group. Extended follow-up data were obtained for approximately 10 years after completion of the trial...
  20. ncbi Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
    B Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Room 3634, 2160 S First Ave, Maywood, IL 60153
    Arch Neurol 57:1439-43. 2000
    ..Increasing evidence suggests that cholesterol plays a role in the pathophysiology of Alzheimer disease (AD). For instance, an elevated serum cholesterol level has been shown to be a risk factor for AD...
  21. ncbi The safety of statins in clinical practice
    Jane Armitage
    Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
    Lancet 370:1781-90. 2007
    ..For most people, statins are safe and well-tolerated, and their widespread use has the potential to have a major effect on the global burden of cardiovascular disease...
  22. ncbi Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
    Stephen J Nicholls
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    JAMA 297:499-508. 2007
    ..However, no data exist describing the relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and disease progression...
  23. ncbi Adherence with statin therapy in elderly patients with and without acute coronary syndromes
    Cynthia A Jackevicius
    Department of Health Policy, Management, and Evaluation, Pharmacy Department and Women s Health Program, University Health Network Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4
    JAMA 288:462-7. 2002
    ..Research prior to these trials of older lipid-lowering agents demonstrated low levels of 1-year adherence...
  24. ncbi Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
    ..0 mmol/L was achieved by 79% to 92% in rosuvastatin groups compared with 52% to 81% in atorvastatin groups. Drug tolerability was similar across treatments...
  25. doi Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis
    P M Kearney
    Lancet 371:117-25. 2008
    ..We undertook a prospective meta-analysis to help resolve these uncertainties...
  26. ncbi Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Helen M Colhoun
    EURODIAB, Department of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Lancet 364:685-96. 2004
    ..We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol...
  27. ncbi Statin-associated myopathy
    Paul D Thompson
    Preventive Cardiology and Cardiovascular Research, Division of Cardiology, Hartford Hospital, Hartford, Conn 06102, USA
    JAMA 289:1681-90. 2003
    ..How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance...
  28. ncbi Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study
    Vincenzo Pasceri
    Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy
    Circulation 110:674-8. 2004
    ..Observational studies have suggested that statins may lower the risk of procedural myocardial injury. The aim of our study was to confirm this hypothesis in a randomized study...
  29. ncbi Statins and the risk of colorectal cancer
    Jenny N Poynter
    Department of Epidemiology, University of Michigan, Ann Arbor 48109 0638, USA
    N Engl J Med 352:2184-92. 2005
    ..Statins inhibit the growth of colon-cancer cell lines, and secondary analyses of some, but not all, clinical trials suggest that they reduce the risk of colorectal cancer...
  30. ncbi A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis
    S Joanna Cowell
    Department of Cardiology, Royal Infirmary, Edinburgh, United Kingdom
    N Engl J Med 352:2389-97. 2005
    ..We hypothesized that intensive lipid-lowering therapy would halt the progression of calcific aortic stenosis or induce its regression...
  31. ncbi Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 80:565-81. 2006
    ..Knowledge of the pharmacokinetic and pharmacodynamic properties of lipid-lowering drugs and their interaction mechanisms helps to avoid adverse interactions, without compromising therapeutic benefits...
  32. ncbi High-dose atorvastatin after stroke or transient ischemic attack
    Pierre Amarenco
    Denis Diderot University, Paris
    N Engl J Med 355:549-59. 2006
    ..Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established...
  33. ncbi HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis
    W W L Wong
    Department of Cellular and Molecular Biology, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Leukemia 16:508-19. 2002
    ..In this article, the experimental evidence supporting a role for the statin family of drugs to this new application will be reviewed...
  34. ncbi Statins and sepsis: multiple modifications at multiple levels
    Marius Terblanche
    Department of Critical Care Medicine, St Thomas Hospital, London, UK
    Lancet Infect Dis 7:358-68. 2007
    ..This work establishes the biological plausibility needed for future trials of statins in critical illness...
  35. ncbi Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Atherosclerosis 204:208-15. 2009
    ..To evaluate a new formulation of fenofibric acid (ABT-335) co-administered with 2 doses of rosuvastatin in patients with mixed dyslipidemia...
  36. ncbi Serum lipoprotein levels, statin use, and cognitive function in older women
    Kristine Yaffe
    Departments of Psychiatry and Neurology, University of California, San Francisco, 4150 Clement St, Campus Box 111G, San Francisco, CA 94121, USA
    Arch Neurol 59:378-84. 2002
    ..Serum lipoprotein levels may be important predictors of cognitive function, and drugs that lower cholesterol may be effective for the prevention of cognitive impairment...
  37. ncbi Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
    A Keech
    Lancet 366:1849-61. 2005
    ..We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients...
  38. doi SLCO1B1 variants and statin-induced myopathy--a genomewide study
    E Link
    N Engl J Med 359:789-99. 2008
    ..In rare cases, myopathy occurs in association with statin therapy, especially when the statins are administered at higher doses and with certain other medications...
  39. ncbi Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease
    P Michael Ho
    Cardiology Section, Denver VA Medical Center, Denver, CO, USA
    Am Heart J 155:772-9. 2008
    ..Little is known about the effect of nonadherence among patients with coronary artery disease (CAD) on a broad spectrum of outcomes including cardiovascular mortality, cardiovascular hospitalizations, and revascularization procedures...
  40. ncbi Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
    C Kyrklund
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 69:340-5. 2001
    ..The risk of developing myopathy during concomitant therapy with lovastatin and a fibrate may be smaller with bezafibrate than with gemfibrozil...
  41. pmc Statin adherence and risk of accidents: a cautionary tale
    Colin R Dormuth
    Therapeutics Initiative, and Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Victoria, BC, Canada
    Circulation 119:2051-7. 2009
    ..We sought evidence of this bias by examining associations between statin exposure and various outcomes that should not be causally affected by statin exposure, such as workplace and motor vehicle accidents...
  42. ncbi Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators
    P M Ridker
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 98:839-44. 1998
    ..We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk...
  43. ncbi Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)
    Timo E Strandberg
    Department of Medicine, University of Helsinki, Helsinki, PL 340, 00029 HUS, Finland
    Lancet 364:771-7. 2004
    ..We extended post-trial follow-up of participants in the Scandinavian Simvastatin Survival Study (4S) to investigate cause-specific mortality and incidence of cancer 5 years after closure of the trial...
  44. ncbi New insights into the pharmacodynamic and pharmacokinetic properties of statins
    A Corsini
    Institute of Pharmacological Sciences, University of Milan, Italy
    Pharmacol Ther 84:413-28. 1999
    ..Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy...
  45. ncbi The risk of cancer in users of statins
    Matthijs R Graaf
    Departments of Clinical Pharmacy and Oncology, Amsterdam, The Netherlands
    J Clin Oncol 22:2388-94. 2004
    ..The objective of this study was to compare the risk of incident cancer between users of statins and users of other cardiovascular medication...
  46. ncbi Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    Lars Ryden
    Department of Cardiology, Karolinska University Hospital, Sweden
    Eur Heart J 28:88-136. 2007
  47. ncbi Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients
    Kwang Kon Koh
    Cardiology, Vascular Medicine and Atherosclerosis Unit, Gil Heart Center, Gachon Medical School, 1198 Kuwol dong, Namdong gu, Incheon, Korea
    Circulation 110:3687-92. 2004
    ..Therefore, we compared vascular and metabolic responses to these therapies either alone or in combination in hypercholesterolemic, hypertensive patients...
  48. pmc Isoprenoids as mediators of the biological effects of statins
    James K Liao
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02139, USA
    J Clin Invest 110:285-8. 2002
  49. ncbi Statin-associated memory loss: analysis of 60 case reports and review of the literature
    Leslie R Wagstaff
    Drug Information Service, Duke University Medical Center, Durham, North Carolina 27710, USA
    Pharmacotherapy 23:871-80. 2003
    ..To review case reports of statin-associated memory loss as well as the available published evidence for and against such a link...
  50. ncbi Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control
    M Nakata
    Department of Physiology, Division of Integrative Physiology, Jichi Medical University, School of Medicine, Shimotsuke, Tochigi 329 0498, Japan
    Diabetologia 49:1881-92. 2006
    ..Based on these findings, the aim of this study was to investigate the effects of statins on adipocytes, which play pivotal roles in glucose metabolism...
  51. ncbi Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)
    Prakash Deedwania
    UCSF School of Medicine, San Francisco, Calif, USA
    Circulation 115:700-7. 2007
    ..However, no studies to date have assessed intensive versus moderate statin therapy in older patients with stable coronary syndromes...
  52. ncbi Risks associated with statin therapy: a systematic overview of randomized clinical trials
    Amir Kashani
    Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Conn, USA
    Circulation 114:2788-97. 2006
    ..We performed a systematic overview of randomized statin trials to quantify the risks of musculoskeletal, renal, and hepatic complications associated with therapy...
  53. ncbi Effect of pravastatin on cardiovascular events in people with chronic kidney disease
    Marcello Tonelli
    Division of Nephrology, University of Alberta, 7 129 Clinical Science Building, 8440 112 St, Edmonton, Alberta T6G 2G3, Canada
    Circulation 110:1557-63. 2004
    ..The objective of this analysis was to determine whether pravastatin reduced the incidence of cardiovascular events in people with or at high risk for coronary disease and with concomitant moderate CKD...
  54. ncbi Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK
    Clin J Am Soc Nephrol 2:1131-9. 2007
    ..This subanalysis of the Treating to New Targets study investigated how intensive lipid lowering with 80 mg of atorvastatin affects renal function when compared with 10 mg in patients with coronary heart disease...
  55. ncbi Rosuvastatin in older patients with systolic heart failure
    John Kjekshus
    Department of Cardiology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway
    N Engl J Med 357:2248-61. 2007
    ..Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients...
  56. ncbi Statins and cancer risk: a meta-analysis
    Krista M Dale
    University of Connecticut School of Pharmacy, Storrs, Conn, USA
    JAMA 295:74-80. 2006
    ..Statins are cholesterol-lowering drugs that have been proven in randomized controlled trials to prevent cardiac events. Recent retrospective analyses have suggested that statins also prevent cancer...
  57. ncbi Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study
    Puja R Myles
    Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, UK
    Pharmacoepidemiol Drug Saf 18:269-75. 2009
    ..The evidence is conflicting however. Our aim was to investigate the effect of these drugs on pneumonia using population-based data from the UK...
  58. ncbi Adverse effects of statins - mechanisms and consequences
    Jerzy Bełtowski
    Department of Pathophysiology, Medical University, Lublin, Poland
    Curr Drug Saf 4:209-28. 2009
    ....
  59. ncbi The Rac and Rho hall of fame: a decade of hypertrophic signaling hits
    Joan Heller Brown
    Department of Pharmacology, University of California, San Diego, USA
    Circ Res 98:730-42. 2006
    ..In this review, we assess the evolution of knowledge related to Rac1 and RhoA in the context of hypertrophy and heart failure and highlight the direction that future exploration will lead...
  60. pmc Rho GTPases, statins, and nitric oxide
    Yoshiyuki Rikitake
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circ Res 97:1232-5. 2005
    ..The regulation of eNOS by Rho GTPases, therefore, may be an important mechanism underlying the cardiovascular protective effect of statins...
  61. ncbi Cholesterol, statins and cancer
    Andrew J Brown
    School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia
    Clin Exp Pharmacol Physiol 34:135-41. 2007
    ..In particular, how the sterol-regulatory element binding protein, Akt and Hedgehog pathways may converge in cancer is reviewed...
  62. ncbi Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease
    G B John Mancini
    Division of Cardiology, Vancouver Hospital, Jack Bell Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 47:2554-60. 2006
    The purpose of this study was to determine if statins (hydroxymethylglutaryl CoA reductase inhibitors [HMG-CoA]), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) reduce cardiovascular (CV) events ..
  63. ncbi Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Adv Cardiol 45:127-53. 2008
    ....
  64. ncbi Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis
    Eric M Mortensen
    VERDICT Research Center, South Texas Veterans Health Care System, San Antonio, Texas 78284, USA
    Pharmacotherapy 27:1619-26. 2007
    ..To examine the effect of previous outpatient use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and/or angiotensin II receptor blockers (ARBs) on 30-day mortality in patients hospitalized with sepsis...
  65. pmc The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
    J J Brugts
    Department of Cardiology, Erasmus MC Thoraxcenter, 3015 GD, Rotterdam, Netherlands
    BMJ 338:b2376. 2009
    ....
  66. ncbi Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome
    Richard W Nesto
    Department of Cardiovascular Medicine, Lahey Clinic, Burlington, Massachusetts 02493, USA
    Am J Cardiovasc Drugs 5:379-87. 2005
    ....
  67. ncbi Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
    Michael Schachter
    Department of Clinical Pharmacology, National Heart and Lung Institute, Imperial College School of Medicine, St Mary s Hospital, London, W2 4NY, UK
    Fundam Clin Pharmacol 19:117-25. 2005
    ..Consideration of the differences between the statins helps to provide a rational basis for their use in clinical practice...
  68. ncbi Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    B G Brown
    Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA
    N Engl J Med 345:1583-92. 2001
    ..CONCLUSIONS: Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels. The use of antioxidant vitamins in this setting must be questioned...
  69. ncbi Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia
    Haralampos J Milionis
    Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
    Am Heart J 148:635-40. 2004
    ..In addition to fenofibrate, there is some evidence that atorvastatin may have a hypouricemic action, but the underlying mechanisms remain speculative...
  70. pmc Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials
    Liam Smeeth
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
    Br J Clin Pharmacol 67:99-109. 2009
    ..To assess the effect of statins on a range of health outcomes...
  71. ncbi MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway
    Megumi Hiraoka
    Department of Medical Biochemistry, Graduate School of Medicine, Tokyo Medical and Dental University, 1 5 45 Yushima Building D 256, Bunkyo, Tokyo 113 8519, Japan
    Life Sci 75:1333-41. 2004
    ..These findings indicate a role for pitavastatin in modulating the MCP-1-induced phenotypic changes of monocyte-endothelial interactions, which may account for the anti-inflammatory effects of statins...
  72. pmc Statin therapy and autoimmune disease: from protein prenylation to immunomodulation
    John Greenwood
    Department of Cell Biology, Institute of Ophthalmology, University College London, London EC1V 9EL, UK
    Nat Rev Immunol 6:358-70. 2006
    ..In this Review, the effect of statin therapy on immune function, and how this relates to the pathogenesis of autoimmune disease, is reviewed alongside current opinion of what the key biological targets of statins are...
  73. ncbi Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation
    Camilla Smith
    Research Institute for Internal Medicine, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
    J Am Coll Cardiol 48:1591-9. 2006
    ..We sought to investigate the role of the CXC chemokine neutrophil-activating peptide-2 (NAP-2) in atherogenesis and plaque destabilization...
  74. ncbi Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
    Marc A Pfeffer
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 105:2341-6. 2002
    ..Therapeutic decisions regarding pharmacological therapy should be based on safety and tolerability as well as efficacy data. Clinical trials designed to assess efficacy are often insufficiently powered to generate reliable safety data...
  75. ncbi Abdominal aortic aneurysm: pathogenesis and implications for management
    Jonathan Golledge
    The Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Queensland 4811, Australia
    Arterioscler Thromb Vasc Biol 26:2605-13. 2006
    ..Well designed large multicenter randomized controlled trials are required to examine the medical treatment of AAA...
  76. ncbi An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
    M Aikawa
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 103:276-83. 2001
    ..Lipid lowering with HMG-CoA reductase inhibitors reduces acute coronary events...
  77. pmc Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1
    Jean Francois Giguere
    Research Center in Infectious Diseases, RC709, CHUL Research Center and Faculty of Medicine, Laval University, Quebec, Canada G1V 4G2
    J Virol 78:12062-5. 2004
    ..The capacity of statins to limit the initial steps in virus replication could represent an interesting approach for the treatment of HIV-1 infection...
  78. pmc Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study
    L Wei
    Medicines Monitoring Unit, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK
    Heart 88:229-33. 2002
    ..To investigate patients' adherence to statin treatment prescribed following their first myocardial infarction (MI) and to estimate the effect of adherence to statins on recurrence of MI and all cause mortality...
  79. pmc Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003
    T Walley
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembrooke Place, Liverpool L69 3GF, UK
    Br J Clin Pharmacol 60:543-51. 2005
    ..To describe trends in utilization and prescribing of statins and other lipid lowering drugs across Europe from data in routine administrative databases...
  80. ncbi Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan
    Takafumi Hiro
    Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
    J Am Coll Cardiol 54:293-302. 2009
    ....
  81. ncbi Extended-release niacin or ezetimibe and carotid intima-media thickness
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA
    N Engl J Med 361:2113-22. 2009
    ....
  82. ncbi C-reactive protein levels and outcomes after statin therapy
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 352:20-8. 2005
    ..Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown...
  83. pmc National trends in statin use by coronary heart disease risk category
    Jun Ma
    Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California, USA
    PLoS Med 2:e123. 2005
    ..Only limited research tracks United States trends in the use of statins recorded during outpatient visits, particularly use by patients at moderate to high cardiovascular risk...
  84. ncbi Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats
    Alexandre Giusti-Paiva
    Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, SP, Brazil
    Shock 21:271-5. 2004
    ..These data suggest the potential use of HMG-CoA reductase inhibitors as a coadjuvant in the treatment of septic shock...
  85. ncbi Statin therapy and risks for death and hospitalization in chronic heart failure
    Alan S Go
    Division of Research, Kaiser Permanente of Northern California, Oakland 94612, USA
    JAMA 296:2105-11. 2006
    ..Whether statin therapy has beneficial effects on clinical outcomes in patients with heart failure is unclear...
  86. ncbi High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial
    Hannu Päivä
    Department of Internal Medicine, University Hospital of Tampere, Finland
    Clin Pharmacol Ther 78:60-8. 2005
    ..This study was designed to assess the effect of high-dose statin treatment on cholesterol and ubiquinone metabolism and mitochondrial function in human skeletal muscle...
  87. ncbi Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial
    Ming Yuan Tseng
    Department of Neurosurgery, Addenbrooke s Hospital, University of Cambridge, Cambridge CB2 2QQ, United Kingdom
    Stroke 36:1627-32. 2005
    ....
  88. ncbi Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials
    Pasquale Strazzullo
    Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy
    Hypertension 49:792-8. 2007
    ..In conclusion, statin therapy has a relatively small but statistically significant and clinically meaningful effect on blood pressure...
  89. ncbi Assessment of the efficacy of different statins in murine collagen-induced arthritis
    Gaby Palmer
    University Hospital and University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Rheum 50:4051-9. 2004
    ..The aim of this study was to further investigate in vivo effects of 3 different statins, atorvastatin, rosuvastatin, and simvastatin, using the same experimental model...
  90. ncbi Structural mechanism for statin inhibition of HMG-CoA reductase
    E S Istvan
    Department of Biochemistry, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center at Dallas, TX 75390 9050, USA
    Science 292:1160-4. 2001
    ..Near the carboxyl terminus of HMGR, several catalytically relevant residues are disordered in the enzyme-statin complexes. If these residues were not flexible, they would sterically hinder statin binding...
  91. ncbi A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense
    Michael B Fessler
    Department of Medicine, National Jewish Medical and Research Center, 1400 Jackson Street, D403 Neustadt, Denver, CO 80206, USA
    Am J Respir Crit Care Med 171:606-15. 2005
    ..No studies to date, however, have addressed whether statins modulate pulmonary inflammation triggered by aerogenic stimuli or whether they affect host defense...
  92. ncbi Beyond lipid lowering: the role of statins in vascular protection
    James K Liao
    Vascular Medicine Research, Brigham and Women s Hospital, 65 Landsdowne Street, Room 275, Cambridge, MA 02139, USA
    Int J Cardiol 86:5-18. 2002
    ....
  93. ncbi Role for protein geranylgeranylation in adult T-cell leukemia cell survival
    Mizuho Nonaka
    Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University, 1 5 45 Bunkyo Ku, Tokyo 113 8510, Japan
    Exp Cell Res 315:141-50. 2009
    ..These results not only unveil an important role for protein geranylgeranylation in ATL cell survival, but also implicate therapeutic potentials of statins in the treatment of ATL...
  94. ncbi Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
    N Glorioso
    Clinica Medica, University of Sassari, Medical School, Sassari, Italy
    Hypertension 34:1281-6. 1999
    ..Pravastatin decreases systolic, diastolic, and pulse pressures in persons with moderate hypercholesterolemia and hypertension. This antihypertensive effect may contribute to the documented health benefits of certain statins...
  95. ncbi Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells
    Toshihiko Nishimura
    Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, Calif 94305 5236, USA
    Circulation 108:1640-5. 2003
    ..The present study was undertaken to investigate the efficacy of simvastatin and its mechanism of reversing established neointimal vascular occlusion and pulmonary hypertension...
  96. ncbi Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins
    Floyd J Frost
    Health and Environmental Epidemiology Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA
    Chest 131:1006-12. 2007
    ..We assessed whether statin users had reduced mortality risks from these conditions...
  97. ncbi Reduction in mortality associated with statin therapy in patients with severe sepsis
    Paul P Dobesh
    College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198 6045, USA
    Pharmacotherapy 29:621-30. 2009
    ..To evaluate the effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) on mortality in patients with severe sepsis...
  98. ncbi Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond
    S I McFarlane
    Division of Endocrinology, Diabetes and Hypertension, Departments of Medicine and Cell Biology, State University of New York Health Science Center, Brooklyn, New York 11203, USA
    J Clin Endocrinol Metab 87:1451-8. 2002
    ..Potential beneficial pleiotropic effects of statins are covered in this review...
  99. ncbi High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:1560-6. 2003
    ..Although statins reduce inflammatory markers in asymptomatic adults or in patients with stable angina, the effect of statins on the markedly heightened inflammation in patients with acute coronary syndromes is unknown...
  100. ncbi Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
    P M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 344:1959-65. 2001
    ..We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia...
  101. ncbi Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations
    Peter C Austin
    Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
    Biom J 51:171-84. 2009
    ..2 of the standard deviation of the logit of the propensity score and the use of calipers of width 0.02 and 0.03 tended to have superior performance for estimating treatment effects...

Research Grants63

  1. A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2009
    ..We aim to investigate safe but innovative therapies which could remodel the pulmonary vasculature and improve outcomes in this currently incurable disease. ..
  2. Statins for Pulmonary and Cardiac Complications of Chronic HIV (The SPARC Trial)
    Stephen R Wisniewski; Fiscal Year: 2013
    ....
  3. STATINS AND ACE INHIBITORS IN ADULTS WITH DIABETES AND COMORBID CONDITIONS
    David E Grembowski; Fiscal Year: 2010
    ....
  4. Role of Oxidative Stress and Inflammation in HIV Cardiovascular Risk
    Cecilia M Shikuma; Fiscal Year: 2012
    ..End of Abstract) ..
  5. Statins protect against adverse cardiac events during pneumonia
    Carlos J Orihuela; Fiscal Year: 2012
    ..The goal of this proposal is to test if statins protect mice against heart damage during pneumonia. ..
  6. Redox Regulation of p21ras in Angiogenesis
    Richard A Cohen; Fiscal Year: 2013
    ..By understanding the molecular mechanisms by which angiogenesis is normally redox-regulated by p21ras and GRX1, we anticipate being able to determine why angiogenesis is impaired in metabolic disease. ..
  7. Prev. of Cardiovas. Complications of Pediatric SLE: Artherosclerosis Prev in Pedi
    Laura E Schanberg; Fiscal Year: 2009
    ..abstract_text> ..
  8. Atrogin-1 and Muscle Protein Balance
    Stewart H Lecker; Fiscal Year: 2010
    ..These studies of atrogin-1 function will help elucidate how the body regulates muscle size, and will ultimately lead to development of drugs to combat muscle wasting. ..
  9. The Interactive Cholesterol Advisory Tool (ICAT)
    CHARLES SCOTT RIGBY; Fiscal Year: 2011
    ..abstract_text> ..
  10. Are Cardioprotective Medications Effective in ESRD?
    Theresa I Shireman; Fiscal Year: 2011
    ..This project will evaluate the effectiveness of cardioprotective medications in reducing cardiac deaths and hospitalizations in ESRD patients. ..
  11. Protection against acute inflammatory demyelinating peripheral nerve disease
    EVAN STUBBS; Fiscal Year: 2009
    ....
  12. Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation
    Elaine Hylek; Fiscal Year: 2012
    ....
  13. An Animal Model of Diabetic Autonomic Neuropathy: Study of Mechanism and Therapy
    JONAS BERNARD GALPER; Fiscal Year: 2010
    ..This model offers a unique opportunity for new insights into mechanism and therapy of DAN and its relationship to arrhythmia and sudden death. ..
  14. Effect of High-Dose Atorvastatin on Neuronal Activity and Cognitive Function
    Donna Polk; Fiscal Year: 2012
    ..End of Abstract) ..
  15. The Effect of Statins on Skeletal Muscle Function
    PAUL DAVIS THOMPSON; Fiscal Year: 2010
    ....
  16. Genetic Risk Stratification to Identify Individuals for Early Statin Therapy
    Marc S Sabatine; Fiscal Year: 2010
    ..Validation of such information would pave the way for launching an economical, feasible, and safe trial of the clinical benefit of statin therapy in young to middle-aged individuals who currently do not qualify for statin therapy. ..
  17. The Role of Statins in Cutaneous Wound Healing
    Marjana Tomic-Canic; Fiscal Year: 2012
    ....
  18. Comparative Effectiveness of Treatment Combinations Post MI in the Elderly
    Mary Schroeder; Fiscal Year: 2013
    ....
  19. Natural Language Processing to Study Epidemiology of Statin Side Effects
    Alexander Turchin; Fiscal Year: 2010
    ..If successful, this approach can be subsequently generalized to study side effects of many other medications. ..
  20. Effect of CoQ10 on Mild-to-Moderate Muscle Symptoms of Statin Users.
    Catherine Buettner; Fiscal Year: 2013
    ..The applicant's long-term goal is to become a leader and expert in research on dietary supplement use among individuals with cardiovascular risk factors or disease. ..
  21. Determining Therapeutic Efficacy of AGE in AD
    Neelima Chauhan; Fiscal Year: 2005
    ..If successful, this project will validate the use of safe, naturally well-tolerated, cost-effective and alternative herbal pharmacotherapy for treating AD. ..
  22. Using Nudges to Implement Comparative Effectiveness: Behavioral Economics and Sta
    NIRAV RAMESH contact SHAH; Fiscal Year: 2010
    ....
  23. Improved actions of nitrates and statins with L-arginine
    Ruth Caldwell; Fiscal Year: 2003
    ..3. Develop an IV formulation of GTN in combination with L-arginine and an oral combined sustained release formulation of ISMN and L-arginine. 4. Develop an oral combined sustained release formulation of SIM and L-arginine. ..
  24. The Role of Statin Lactones in Statin Toxicity
    Uwe Christians; Fiscal Year: 2006
    ..Our secondary goal will be to compare the lactones/acids of the different statins with each other. ..
  25. Ethyl Nitrite and Subarachnoid Hemorrhage
    Huaxin Sheng; Fiscal Year: 2009
    ....
  26. Statin-Berberine Combination Therapy in Hyperlipidemia
    Jingwen Liu; Fiscal Year: 2009
    ..The success of these studies will ultimately benefit patients by offering more choices for their individual needs in reducing plasma cholesterol levels to prevent atherosclerotic cardiovascular disease. ..
  27. Effect of Informed Consent on Compliance: Statin Therapy
    MICHAEL CROUCH; Fiscal Year: 2005
    ..abstract_text> ..
  28. Immunomodulation of inflammatory disease by atorvastatin
    Scott Zamvil; Fiscal Year: 2009
    ..These studies have direct and immediate applicability to the use of statins in treatment of autoimmune disease. ..
  29. Pathobiology of HMG-CoA reductase inhibitors in diabetes
    Yashpal Kanwar; Fiscal Year: 2006
    ....
  30. HMG COA REDUCTASE INHIBITORS IN THE ELDERLY--PILOT STUDY
    Robert Knopp; Fiscal Year: 1992
    ..Coronary heart disease related morbidity and mortality, and all cause mortality data will be collected throughout the follow-up...
  31. Medical History, Medications, and Pancreatic Cancer Risk
    MARGARET MANDELSON; Fiscal Year: 2004
    ..abstract_text> ..
  32. HMG COA REDUCTASE INHIBITORS IN THE ELDERLY
    William Applegate; Fiscal Year: 1992
    ..The investigators would participate in all national planning and monitoring activities and are prepared to implement any protocol designed by the steering committee...
  33. Antihyperlipidemic Effects of Oyster Mushrooms
    Donald Abrams; Fiscal Year: 2004
    ..abstract_text> ..
  34. PHARMACOKINETICS OF REVERSIBLE METABOLIC SYSTEMS
    William Jusko; Fiscal Year: 1993
    ....
  35. HMG CoA reductase Inhibitors and cardiopulmonary Bypass
    Tanveer Khan; Fiscal Year: 2002
    ..The results are expected to ultimately contribute to the perioperative management of patients who undergo CPB resulting in improved clinical outcomes. ..
  36. CORONARY VASCULAR RESPONSE TO ISCHEMIA
    ROBERT BACHE; Fiscal Year: 2007
    ..A final study will examine the influence of NO on the energy supply/demand relationship in collateralized myocardium. ..
  37. PATHOPHYSIOLOGY OF THROMBOEMBOLIC STROKE
    W Dietrich; Fiscal Year: 2003
    ..Neuroprotective strategies that may be given to patients with stroke risk factors to prevent the initiation of stroke will be tested. ..
  38. HMG COA REDUCTASE INHIBITORS IN THE ELDERLY
    CLARENCE DAVIS; Fiscal Year: 1992
    ..Also discussed are issues pertinent to the design of the pilot and main trial...
  39. Determinants of Atherosclerotic Plaque Progression
    Stanley Hazen; Fiscal Year: 2004
    ..abstract_text> ..
  40. Endotoxin, Vascular Inflammation and Atherosclerosis
    NEAL WEINTRAUB; Fiscal Year: 2006
    ..The proposed studies will provide novel insight into the mechanisms by which endotoxin-mediated vascular inflammation may contribute to atherosclerosis. ..
  41. Pathogenesis and Therapy of Chronic Lung Rejection
    Marshall Hertz; Fiscal Year: 2005
    ..abstract_text> ..
  42. Trangenic Mouse Model of Alzheimer's Disease
    John Lynch; Fiscal Year: 2005
    ..Ultimately, this may lead to novel therapeutic strategies that are translatable for use in clinical trials. ..
  43. HMG COA REDUCTASE INHIBITORS IN THE ELDERLY
    Donald Hunninghake; Fiscal Year: 1992
    ....
  44. Combined Therapeutic-Imaging Agent for Atherosclerosis
    Gregory Lanza; Fiscal Year: 2007
    ..This novel application of molecular imaging and targeted drug delivery could serve as part of a primary prevention strategy to diagnose, treat, and monitor early atherosclerosis. [unreadable] [unreadable] [unreadable]..
  45. Effects of HMG-coA Reductase Pathway Inhibitors on GCAD
    William Stein; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  46. HMG COA REDUCTASE INHIBITORS IN THE ELDERLY
    JOHN CROUSE; Fiscal Year: 1992
    ..a coordinated drug-dosage scheme to titrate drug dose to achieve target LDL concentrations. With the proposed clinic design the study can be implemented at a reasonable cost...
  47. Do Statins Ameliorate Periodontal Disease?
    Barry Saver; Fiscal Year: 2005
    ....
  48. IN VITRO PRESCREENING OF CLASSES OF CHEMOPREVENTIVES
    JOHN PEZZUTO; Fiscal Year: 1999
    ..There are ten agents in each mechanistic category to assay and to determine dose-related effects. ..
  49. Cell cycle regulation of pulmonary vascular remodeling
    Brian Fouty; Fiscal Year: 2007
    ..This information may lead to more targeted therapy for the treatment of PHTN. ..
  50. Statins and Macrophage Immune Functions
    Elizabeth Gold; Fiscal Year: 2007
    ..However, their lipid lowering properties incompletely explain the beneficial effect of these drugs. ..
  51. SAFETY & EFFICACY OF ATORVASTATIN IN NEWLY DIAGNOSED TYPE 1 DIABETES
    STEVEN WILLI; Fiscal Year: 2009
    ..The ability to significantly delay the further loss of beta cells in these patients would dramatically improve diabetes control, lessen the likelihood of complications and improve quality of life. ..
  52. A Murine Model for Inhibition of Farnesyltransferase
    Guy Zimmerman; Fiscal Year: 2009
    ....
  53. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
    ....
  54. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2002
    ....
  55. MIDCAREER INVESTIGATOR AWARD IN CEREBROVASCULAR RESEARCH
    Larry Goldstein; Fiscal Year: 2004
    ....
  56. AMPHETAMINE ENHANCED STROKE RECOVERY--BURKE SRCI GROUP
    Larry Goldstein; Fiscal Year: 2002
    ..However the treatment duration will be increased to a total of 10 sessions. ..
  57. Medication and Colorectal Cancer Risk
    Denise Boudreau; Fiscal Year: 2005
    ..abstract_text> ..
  58. Role of PI3-Kinase in Estrogen-induced eNOS Activation
    James Liao; Fiscal Year: 2007
    ..These results may explain some of the actions of selective estrogen receptor modulators (SERMs) and provide a therapeutic basis for using estrogens in cardiovascular disease. ..
  59. Coenzyme Q10 in Aging: A Planning Grant
    Beatrice Golomb; Fiscal Year: 2005
    ..Thus there is strong conceptual as well as clinical rationale for assessing whether Q10 provides QOL & functional benefits in aging and whether it protects against untoward events associated with age. ..
  60. Activation of eNOS by Steroid Hormones
    James Liao; Fiscal Year: 2006
    ....
  61. Endothelial Akt in Vascular Injury
    James Liao; Fiscal Year: 2009
    ..Three specific aims are proposed, which will study the role of endothelial Akt in models of vascular injury and atherosclerosis. ..
  62. Satin Use and the Risk of Site Specific Cancers
    Denise Boudreau; Fiscal Year: 2005
    ..abstract_text> ..